Quadrature Capital Ltd cut its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 91.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 40,767 shares of the company's stock after selling 435,910 shares during the period. Quadrature Capital Ltd's holdings in Kenvue were worth $943,000 at the end of the most recent quarter.
Several other institutional investors also recently added to or reduced their stakes in KVUE. Riverview Trust Co purchased a new stake in shares of Kenvue in the 3rd quarter worth $30,000. Ashton Thomas Securities LLC purchased a new stake in Kenvue in the third quarter worth about $35,000. Studio Investment Management LLC grew its holdings in Kenvue by 52.1% during the 2nd quarter. Studio Investment Management LLC now owns 2,468 shares of the company's stock worth $45,000 after acquiring an additional 845 shares in the last quarter. Deseret Mutual Benefit Administrators grew its holdings in Kenvue by 49.7% during the 3rd quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company's stock worth $45,000 after acquiring an additional 651 shares in the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA purchased a new position in Kenvue during the 2nd quarter valued at about $61,000. Hedge funds and other institutional investors own 97.64% of the company's stock.
Analyst Upgrades and Downgrades
A number of brokerages have recently issued reports on KVUE. JPMorgan Chase & Co. lifted their price target on Kenvue from $24.00 to $25.00 and gave the company an "overweight" rating in a report on Friday, October 11th. Jefferies Financial Group assumed coverage on Kenvue in a research note on Tuesday, September 24th. They issued a "buy" rating and a $27.00 target price on the stock. Piper Sandler increased their price target on shares of Kenvue from $20.00 to $21.00 and gave the company a "neutral" rating in a research report on Monday, September 23rd. Royal Bank of Canada cut shares of Kenvue from an "outperform" rating to a "sector perform" rating and set a $24.00 price target on the stock. in a report on Tuesday, September 24th. Finally, Bank of America increased their target price on shares of Kenvue from $24.00 to $27.00 and gave the company a "buy" rating in a research report on Tuesday, October 22nd. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, Kenvue presently has a consensus rating of "Hold" and a consensus target price of $22.64.
Get Our Latest Stock Report on Kenvue
Kenvue Stock Performance
KVUE stock traded down $0.29 during trading on Friday, hitting $22.84. 9,708,660 shares of the company traded hands, compared to its average volume of 13,840,819. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46. The stock's 50-day simple moving average is $22.97 and its 200 day simple moving average is $21.10. The company has a market cap of $43.79 billion, a PE ratio of 41.53, a P/E/G ratio of 2.10 and a beta of 1.36.
Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, beating analysts' consensus estimates of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The company had revenue of $3.90 billion during the quarter, compared to analysts' expectations of $3.92 billion. During the same quarter in the previous year, the company earned $0.31 earnings per share. The firm's revenue for the quarter was down .4% on a year-over-year basis. On average, equities analysts expect that Kenvue Inc. will post 1.07 earnings per share for the current fiscal year.
Kenvue Announces Dividend
The business also recently declared a quarterly dividend, which was paid on Wednesday, November 27th. Investors of record on Wednesday, November 13th were issued a $0.205 dividend. This represents a $0.82 annualized dividend and a yield of 3.59%. The ex-dividend date of this dividend was Wednesday, November 13th. Kenvue's payout ratio is presently 149.09%.
About Kenvue
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Read More
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
